Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The FDA granted accelerated approval to Denali’s Hunter syndrome drug, offering patients hope after a string of tougher rare disease decisions. Sarepta, meanwhile, posted early but limited data on new RNA therapies, asking investors to buy back in after a difficult year.
Also, an approval from Corcept after it had an FDA miss with the same drug last year, and we await a high-stakes readout from off-the-shelf CAR-T player Allogene.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
